iBio, Inc. (IBIO)

Market Cap	7.01M
Revenue (ttm)	61,000
Net Income (ttm)	-76.03M
Shares Out	22.61M
EPS (ttm)	-8.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,539
Open	0.304
Previous Close	0.298
Day's Range	0.302 - 0.309
52-Week Range	0.260 - 8.750
Beta	-3.16
Analysts	Hold
Price Target	4.25 (+1,307.29%)
Earnings Date	Nov 13, 2023

About IBIO

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Martin B. Brenner D.V.M., Ph.D.
• Employees: 105
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: IBIO

Financial Performance

In 2022, iBio, Inc.'s revenue was $2.38 million, an increase of 0.51% compared to the previous year's $2.37 million. Losses were -$50.39 million, 114.7% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for IBIO stock is "Hold." The 12-month stock price forecast is $4.25, which is an increase of 1,307.29% from the latest price.

Price Target

$4.25

(1,307.29% upside)

Analyst Consensus: Hold